ClinicalTrials.gg
CompletedNCT02675907Updated Nov 17, 2017Results posted

Evaluation of N1539 Following Bunionectomy Surgery

A Phase 3 interventional study of N1539 and Intravenous Placebo in Pain, Post-operative, sponsored by Baudax Bio. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by Baudax Bio · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.

Enrollment
10th of 24
201 · median 112
Started
2016
with 2 others
Phase 3
9 of 24
none open now
Registered
3rd of 24
by date
Lead sponsor
7 of 24
Baudax Bio

Among the 24 studies testing meloxicam in Pain, Postoperative, this one is the 10th largest by enrollment, is one of 3 that started in 2016, is one of 9 in phase 3, and was the 3rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing meloxicam in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following unilateral bunionectomy.

03

Conditions studied

  • Pain, Post-operative

Keywords

  • Bunion
  • Bunionectomy
  • Pain
  • Analgesia
  • N1539
  • Phase 3
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily provide written .
  • Male or female between 18 and 75 years of age, inclusive.
  • Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair
  • Be American Society of Anesthesiology (ASA) physical class 1 or 2.
  • Female subject are eligible only if all the following apply:

    • Not pregnant;
    • Not lactating;
    • Not planning to become pregnant during the study;
    • Commit to the use of an acceptable form of for the duration of the study.
  • Have a ≤35 kg/m2
  • Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program.

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy to meloxicam or any of N1539, D5W, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or to any peri- or postoperative medications used in this study.
  • Have a abnormal clinical laboratory test value.
  • Have history of or positive test results for , or or C.
  • Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study.
  • Have a history of myocardial infarction or coronary artery bypass graft surgery within the preceding 12 months
  • Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
  • Have active or recent (within 6 months) gastrointestinal ulceration or bleeding.
  • Have a known bleeding disorder or be taking agents affecting coagulation
  • Have another painful physical condition that may confound the assessments of post operative pain.
  • Have evidence of a clinically significant 12 lead abnormality.
  • Have a history of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) within the past 5 years or a history of prescription/illicit drug abuse.
  • Have positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
  • Have been receiving or have received chronic opioid therapy defined as greater than 15 morphine equivalents units per day for greater than 3 out of 7 days per week over a one-month period within 12 months of surgery.
  • Use concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the investigator's opinion may exert significant analgesic properties or act synergistically with N1539.
  • Unable to discontinue medications, that have not been at a stable dose for at least 14 days prior to the scheduled bunionectomy procedure, within 5 half lives of the specific prior medication (or, if half life is not known, within 48 hours) before dosing with study medication.
  • Have utilized , either systemically or by intra-articular injection, within 6 weeks prior to the surgical procedure.
  • Have received any product within 30 days before dosing with study medication.
  • Be receiving warfarin, lithium, or a combination of furosemide with either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker
  • Be currently receiving treatment with oral meloxicam (Mobic®) within 7 days prior to surgery
  • Have previously received N1539 in clinical trials, or had major surgery in the last 3 months that would interfere with study outcomes or increase the risk of study participation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    N1539 30mg

    N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.

    Drug: N1539

  • Placebo comparator
    IV Placebo

    IV Placebo every 24 hours for up to 3 doses.

    Drug: Intravenous Placebo

Interventions

  • DrugN1539

    Also known as: Intravenous meloxicam

  • DrugIntravenous Placebo
06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference Over the First 48 Hours (SPID48)

    Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better.

    Time frame: 48 Hours

Secondary outcomes

  1. Summed Pain Intensity Difference (SPID) at Other Intervals

    Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better.

    Time frame: 48 Hours

  2. Time to First Dose of Rescue Analgesia

    Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request. Time to first rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.

    Time frame: 48 Hours

  3. Number of Subjects Utilizing Rescue Analgesia

    Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request.

    Time frame: 48 Hours

  4. Number of Doses of Rescue Analgesia Utilized Per Subject

    Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request.

    Time frame: 48 Hours

  5. Time to Perceptible Pain Relief (TTPPR)

    Time to perceptible and meaningful pain relief was measured using the double stopwatch method. For each randomized subject, two stopwatches were started immediately after administration of the first study dose (Hour 0). The subject was to stop the first watch when they first perceived pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they first experienced meaningful pain relief (time to meaningful relief).

    Time frame: 12 Hours

  6. Time to Meaningful Pain Relief (TTMPR)

    Time to perceptible and meaningful pain relief was measured using the double stopwatch method. For each randomized subject, two stopwatches were started immediately after administration of the first study dose (Hour 0). The subject was to stop the first watch when they first perceived pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they first experienced meaningful pain relief (time to meaningful relief).

    Time frame: 12 Hours

  7. Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 6

    Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 6 = 100 \* SPID6 / (BaselinePI \* 6 \* 60), and SPID6 \< 0 as an indication for improvement.

    Time frame: 6 Hours

  8. Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 24

    Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 24 = 100 \* SPID24 / (BaselinePI \* 24 \* 60), and SPID24 \< 0 as an indication for improvement.

    Time frame: 24 Hours

  9. Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 6

    Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 6 = 100 \* SPID6 / (BaselinePI \* 6 \* 60), and SPID6 \< 0 as an indication for improvement.

    Time frame: 6 Hours

  10. Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 24

    Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 24 = 100 \* SPID24 / (BaselinePI \* 24 \* 60), and SPID24 \< 0 as an indication for improvement.

    Time frame: 24 Hours

  11. Patient Global Assessment (PGA) of Pain Control at Hour 24

    PGA of pain control was evaluated at Hour 24 and Hour 48 with subject reported degree of pain control over the preceding interval according to a 5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent.

    Time frame: 24 Hours

  12. Patient Global Assessment (PGA) of Pain Control at Hour 48

    PGA of pain control was evaluated at Hour 24 and Hour 48 with subject reported degree of pain control over the preceding interval according to a 5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent.

    Time frame: 48 Hours

07

Results

Posted Sep 29, 2017

Participant flow

Treatment Phase (48 Hours Post-Dose 1)
Participant flow — Treatment Phase (48 Hours Post-Dose 1)
MilestoneN1539 30 mgIV Placebo
Started100101
Completed9596
Not completed55
Withdrew: Lack of efficacy44
Withdrew: Withdrawal by subject11
Study Overall
Participant flow — Study Overall
MilestoneN1539 30 mgIV Placebo
Started100101
Completed9797
Not completed34
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up02

Outcome measures

PrimarySummed Pain Intensity Difference Over the First 48 Hours (SPID48)

Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better.

Time frame:
48 Hours
Reported as:
Least squares mean · units on a scale
Summed Pain Intensity Difference Over the First 48 Hours (SPID48)
units on a scaleN1539 30 mgIV Placebo
Summed Pain Intensity Difference Over the First 48 Hours (SPID48)-6956.0 ± 521.69-4829.3 ± 519.56
Statistical analysis
  • N1539 30 mg vs IV Placebo · t-test, 2 sided · p = 0.0034
SecondarySummed Pain Intensity Difference (SPID) at Other Intervals

Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better.

Time frame:
48 Hours
Reported as:
Least squares mean · units on a scale
Summed Pain Intensity Difference (SPID) at Other Intervals
units on a scaleN1539 30 mgIV Placebo
SPID6 (Hour 0-6)-510.78 ± 66.22-288.33 ± 65.95
SPID12 (Hour 0-12)-957.83 ± 123.30-480.15 ± 122.80
SPID24 (Hour 0-24)-2071.0 ± 247.01-1167.9 ± 246.00
SPID12-48 (Hour 12-48)-5998.2 ± 439.21-4349.1 ± 437.42
SPID24-48 (Hour 24-48)-4885.1 ± 313.60-3661.4 ± 312.32
Statistical analysis
  • N1539 30 mg vs IV Placebo · t-test, 2 sided · p = <0.05 (Row 1 (SPID6))
  • N1539 30 mg vs IV Placebo · t-test, 2 sided · p = <0.01 (Row 2 (SPID12))
  • N1539 30 mg vs IV Placebo · t-test, 2 sided · p = <0.01 (Row 3 (SPID24))
  • N1539 30 mg vs IV Placebo · t-test, 2 sided · p = <0.01 (Row 4 (SPID12-48))
  • N1539 30 mg vs IV Placebo · t-test, 2 sided · p = <0.01 (Row 5 (SPID24-48))
SecondaryTime to First Dose of Rescue Analgesia

Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request. Time to first rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.

Time frame:
48 Hours
Reported as:
Median · hours
Time to First Dose of Rescue Analgesia
hoursN1539 30 mgIV Placebo
Time to First Dose of Rescue Analgesia1.99 (1.53 to 4.12)2.09 (1.15 to 3.31)
Statistical analysis
  • N1539 30 mg vs IV Placebo · Log Rank · p = 0.0076
SecondaryNumber of Subjects Utilizing Rescue Analgesia

Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request.

Time frame:
48 Hours
Reported as:
Count of participants · Participants
Number of Subjects Utilizing Rescue Analgesia
ParticipantsN1539 30 mgIV Placebo
Hour 0-248399
Hour 24-484871
Hour 0-488399
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = <0.001 (Row 1 (Hour 0-24))
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = <0.01 (Row 2 (Hour 24-48))
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = <0.01 (Row 3 (Hour 0-48))
SecondaryNumber of Doses of Rescue Analgesia Utilized Per Subject

Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request.

Time frame:
48 Hours
Reported as:
Least squares mean · doses of rescue analgesia
Number of Doses of Rescue Analgesia Utilized Per Subject
doses of rescue analgesiaN1539 30 mgIV Placebo
Hour 0-243.97 ± 0.265.06 ± 0.26
Hour 24-481.63 ± 0.252.51 ± 0.25
Hour 0-485.45 ± 0.467.49 ± 0.46
Statistical analysis
  • N1539 30 mg vs IV Placebo · ANCOVA · p = <0.05 (Row 1 (Hour 0-24))P-values were derived from ANCOVA models with fixed effects of treatment, baseline PI score, and investigational site
  • N1539 30 mg vs IV Placebo · ANCOVA · p = <0.05 (Row 2 (Hour 24-48))P-values were derived from ANCOVA models with fixed effects of treatment, baseline PI score, and investigational site
  • N1539 30 mg vs IV Placebo · ANCOVA · p = <0.05 (Row 3 (Hour 0-48))P-values were derived from ANCOVA models with fixed effects of treatment, baseline PI score, and investigational site
SecondaryTime to Perceptible Pain Relief (TTPPR)

Time to perceptible and meaningful pain relief was measured using the double stopwatch method. For each randomized subject, two stopwatches were started immediately after administration of the first study dose (Hour 0). The subject was to stop the first watch when they first perceived pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they first experienced meaningful pain relief (time to meaningful relief).

Time frame:
12 Hours
Reported as:
Median · hours
Time to Perceptible Pain Relief (TTPPR)
hoursN1539 30 mgIV Placebo
Time to Perceptible Pain Relief (TTPPR)0.52 (0.35 to 0.74)1.59 (0.48 to 2.00)
Statistical analysis
  • N1539 30 mg vs IV Placebo · Log Rank · p = 0.1228
SecondaryTime to Meaningful Pain Relief (TTMPR)

Time to perceptible and meaningful pain relief was measured using the double stopwatch method. For each randomized subject, two stopwatches were started immediately after administration of the first study dose (Hour 0). The subject was to stop the first watch when they first perceived pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they first experienced meaningful pain relief (time to meaningful relief).

Time frame:
12 Hours
Reported as:
Median · hours
Time to Meaningful Pain Relief (TTMPR)
hoursN1539 30 mgIV Placebo
Time to Meaningful Pain Relief (TTMPR)2.16 (1.00 to 12.01)3.19 (2.39 to 4.82)
Statistical analysis
  • N1539 30 mg vs IV Placebo · Log Rank · p = 0.1048
SecondarySubjects With ≥ 30% Improvement in Pain From Baseline to Hour 6

Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 6 = 100 \* SPID6 / (BaselinePI \* 6 \* 60), and SPID6 \< 0 as an indication for improvement.

Time frame:
6 Hours
Reported as:
Count of participants · Participants
Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 6
ParticipantsN1539 30 mgIV Placebo
Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 63220
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = 0.0451
SecondarySubjects With ≥ 30% Improvement in Pain From Baseline to Hour 24

Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 24 = 100 \* SPID24 / (BaselinePI \* 24 \* 60), and SPID24 \< 0 as an indication for improvement.

Time frame:
24 Hours
Reported as:
Count of participants · Participants
Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 24
ParticipantsN1539 30 mgIV Placebo
Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 243721
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = 0.0107
SecondarySubjects With ≥ 50% Improvement in Pain From Baseline to Hour 6

Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 6 = 100 \* SPID6 / (BaselinePI \* 6 \* 60), and SPID6 \< 0 as an indication for improvement.

Time frame:
6 Hours
Reported as:
Count of participants · Participants
Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 6
ParticipantsN1539 30 mgIV Placebo
Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 6168
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = 0.0781
SecondarySubjects With ≥ 50% Improvement in Pain From Baseline to Hour 24

Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 24 = 100 \* SPID24 / (BaselinePI \* 24 \* 60), and SPID24 \< 0 as an indication for improvement.

Time frame:
24 Hours
Reported as:
Count of participants · Participants
Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 24
ParticipantsN1539 30 mgIV Placebo
Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 24135
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = 0.0430
SecondaryPatient Global Assessment (PGA) of Pain Control at Hour 24

PGA of pain control was evaluated at Hour 24 and Hour 48 with subject reported degree of pain control over the preceding interval according to a 5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent.

Time frame:
24 Hours
Reported as:
Count of participants · Participants
Patient Global Assessment (PGA) of Pain Control at Hour 24
ParticipantsN1539 30 mgIV Placebo
0 - Poor1729
1 - Fair2326
2 - Good2826
3 - Very Good1713
4 - Excellent103
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = 0.1070P-value was derived from comparisons between N1539 and Placebo via General Association of CMH Test controlling for investigational site
SecondaryPatient Global Assessment (PGA) of Pain Control at Hour 48

PGA of pain control was evaluated at Hour 24 and Hour 48 with subject reported degree of pain control over the preceding interval according to a 5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent.

Time frame:
48 Hours
Reported as:
Count of participants · Participants
Patient Global Assessment (PGA) of Pain Control at Hour 48
ParticipantsN1539 30 mgIV Placebo
0 - Poor715
1 - Fair818
2 - Good2625
3 - Very Good3030
4 - Excellent248
Statistical analysis
  • N1539 30 mg vs IV Placebo · Cochran-Mantel-Haenszel · p = 0.0046P-value was derived from comparisons between N1539 and Placebo via General Association of CMH Test controlling for investigational site

Adverse events

Collected over AEs collected from time of first dose through last followup (30 days). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N1539 30 mg0/100 (0%)0/100 (0%)44/100 (44%)
IV Placebo1/101 (1%)2/101 (2%)54/101 (53.5%)
Most frequent serious events
Most frequent serious events
EventN1539 30 mgIV Placebo
Sudden deathGeneral disorders0/1001/101
FractureInjury, poisoning and procedural complications0/1001/101
Most frequent other events
Showing 10 of 25
Most frequent other events
EventN1539 30 mgIV Placebo
NauseaGastrointestinal disorders20/10026/101
HeadacheNervous system disorders8/10012/101
VomitingGastrointestinal disorders3/1009/101
PruritusSkin and subcutaneous tissue disorders8/1003/101
Decreased appetiteMetabolism and nutrition disorders2/1007/101
ConstipationGastrointestinal disorders4/1005/101
DizzinessNervous system disorders3/1004/101
SomnolenceNervous system disorders3/1002/101
FlushingVascular disorders3/1001/101
Alanine aminotransferase increasedInvestigations0/1003/101

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)N1539 30 mgIV PlaceboTotal
<=18 years000
Between 18 and 65 years9292184
>=65 years8917
Age, Continuous
Age, Continuous(years)N1539 30 mgIV PlaceboTotal
Mean46.7 ± 12.7948.4 ± 12.1747.6 ± 12.48
Sex: Female, Male
Sex: Female, Male(Participants)N1539 30 mgIV PlaceboTotal
Female8487171
Male161430
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)N1539 30 mgIV PlaceboTotal
Hispanic or Latino283664
Not Hispanic or Latino7265137
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)N1539 30 mgIV PlaceboTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander224
Black or African American322658
White6168129
More than one race325
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)N1539 30 mgIV PlaceboTotal
United States100101201
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)N1539 30 mgIV PlaceboTotal
Mean26.9 ± 4.8028.3 ± 4.0227.6 ± 4.46
Time from End of Surgery to First Dose
Time from End of Surgery to First Dose(hours)N1539 30 mgIV PlaceboTotal
Mean0.514 ± 0.23970.485 ± 0.20010.500 ± 0.2206

1 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Trovare Clinical Research
    Bakersfield, California, United States
  • Lotus Clinical Research
    Pasadena, California, United States
  • Chesapeake Research Group
    Pasadena, Maryland, United States
  • Endeavor Clinical Trials
    San Antonio, Texas, United States
09

References and documents

Publications

  • Viscusi ER, Gan TJ, Bergese S, Singla N, Mack RJ, McCallum SW, Du W, Hobson S. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med. 2019 Mar;44(3):360-368. doi: 10.1136/rapm-2018-100184. Epub 2019 Feb 7. PubMed 30737315 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2016
First posted
Feb 5, 2016
Start
Jan 2016
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Sep 29, 2017
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02675907
Lead sponsor
Baudax Bio
Responsible party
Sponsor
First posted
Feb 5, 2016
Start date
Jan 2016
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Sep 29, 2017
Last update
Nov 17, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion